Discovery and development of SAHA as an anticancer agent (Q36745383)

16 August 2017

1 reference

title

Discovery and development of SAHA as an anticancer agent (English)

1 reference

16 August 2017

Marks PA

1

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 February 2007

1 reference

16 August 2017

1 reference

16 August 2017

volume

26

1 reference

16 August 2017

issue

9

1 reference

16 August 2017

page(s)

1351-1356

1 reference

Physiological functions of thioredoxin and thioredoxin reductase

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210204

Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210204

Potent cytodifferentiating agents related to hexamethylenebisacetamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210204

The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210204

Prospects: histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210204

Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210204

Hemoglobin synthesis in murine virus-induced leukemic cells in vitro: stimulation of erythroid differentiation by dimethyl sulfoxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210204

Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210204

A strategy for identifying transcription factor binding sites reveals two classes of genomic c-Myc target sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210204

Mitochondria: A novel target for the chemoprevention of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210204

Identification of novel isoform-selective inhibitors within class I histone deacetylases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210204

Histone deacetylase inhibitors in cancer therapy: is transcription the primary target?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210204

Drug insight: Histone deacetylase inhibitors--development of the new targeted anticancer agent suberoylanilide hydroxamic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210204

Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210204

Histone acetyltransferases and deacetylases in the control of cell proliferation and differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210204

Screening and identification of differentially expressed transcripts in circulating cells of prostate cancer patients using suppression subtractive hybridization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210204

3-(4-Aroyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-alkylamides as a new class of synthetic histone deacetylase inhibitors. 1. Design, synthesis, biological evaluation, and binding mode studies performed through three different docking procedures

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210204

Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamides

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210204

Erythroleukemic Differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210204

Inhibitors of apoptosis proteins in prostate cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210204

Histone Deacetylase Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210204

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210204

Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210204

The role of the redox protein thioredoxin in cell growth and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210204

A new group of potent inducers of differentiation in murine erythroleukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210204

A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210204

Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210204

Second generation hybrid polar compounds are potent inducers of transformed cell differentiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210204

Rapid alteration of microRNA levels by histone deacetylase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210204

Apoptotic and autophagic cell death induced by histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210204

Global gene expression profiling of circulating tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210204

Induction of erythroid differentiation in murine virus infected eythroleukemia cells by highly polar compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210204

Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210204

Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210204

A novel antisense oligonucleotide inhibiting several antiapoptotic Bcl-2 family members induces apoptosis and enhances chemosensitivity in androgen-independent human prostate cancer PC3 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210204

Epigenetic therapy of cancer: past, present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210204

Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210204

Epigenetic changes in prostate cancer: implication for diagnosis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210204

inferred from DOI database lookup

7 January 2021

based on heuristic

Discovery of (Aryloxopropenyl)pyrrolyl Hydroxyamides as Selective Inhibitors of Class IIa Histone Deacetylase Homologue HD1-A

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210204

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/SJ.ONC.1210204

1 reference

Dimensions Publication ID

16 August 2017

1020984439

0 references

1 reference